DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-3.45%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$334M
AUM Growth
+$334M
(-6.1%)
Cap. Flow
-$2.99M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11
Top Buys
| 1 |
Cytokinetics
CYTK
|
$3.26M |
| 2 |
Century Therapeutics
IPSC
|
$2.89M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$2.51M |
| 4 |
AtriCure
ATRC
|
$2.22M |
| 5 |
Revolution Medicines
RVMD
|
$2.12M |
Top Sells
| 1 |
Fate Therapeutics
FATE
|
$5.56M |
| 2 |
89bio
ETNB
|
$4.13M |
| 3 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
$3.65M |
| 4 |
Viking Therapeutics
VKTX
|
$3.37M |
| 5 |
Biohaven
BHVN
|
$2.15M |
Sector Composition
| 1 | Healthcare | 81.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $43.4M | 13.02% | 570,000 +4,000 | +0.7% | +$305K |
|
2
Stereotaxis
STXS
$261M
| $27.9M | 8.37% | 13,680,554 | – | – |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $14.9M | 4.47% | 612,975 +7,000 | +1% | +$170K |
|
4
Ascendis Pharma
ASND
$11.8B
| $14.5M | 4.35% | 135,212 +5,000 | +4% | +$536K |
|
|
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.3M | 4.28% | 78,573 +6,546 | +9% | +$1.19M |
|
6
iShares Biotechnology ETF
IBB
$5.6B
| $13.2M | 3.97% | 102,500 | – | – |
|
|
7
Revolution Medicines
RVMD
$7.1B
| $12.5M | 3.74% | 575,785 +98,000 | +21% | +$2.12M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $11.8M | 3.52% | 261,235 | – | – |
|
9
Xenon Pharmaceuticals
XENE
$2.98B
| $11.3M | 3.39% | 316,092 | – | – |
|
|
10
Cytokinetics
CYTK
$4.23B
| $9.73M | 2.92% | 276,495 +92,500 | +50% | +$3.26M |
|
11
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.44M | 2.83% | 447,073 | – | – |
|
12
DexCom
DXCM
$29.5B
| $7.85M | 2.35% | 67,552 | – | – |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $7.57M | 2.27% | 180,306 | – | – |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $7.55M | 2.26% | 74,615 +1,494 | +2% | +$151K |
|
|
MORF
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.76M | 2.03% | 179,467 -16,000 | -8% | -$602K |
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $6.43M | 1.93% | 468,358 | – | – |
|
|
CSII
17
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.7M | 1.71% | 286,988 | – | – |
|
|
DICE
18
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $5.37M | 1.61% | 187,585 +64,085 | +52% | +$1.84M |
|
|
19
Viking Therapeutics
VKTX
$3.04B
| $5.31M | 1.59% | 319,155 -202,398 | -39% | -$3.37M |
|
20
Merus
MRUS
$4.98B
| $5.23M | 1.57% | 283,998 +14,105 | +5% | +$260K |
|
|
21
AtriCure
ATRC
$1.84B
| $5.2M | 1.56% | 125,529 +53,500 | +74% | +$2.22M |
|
22
Nurix Therapeutics
NRIX
$714M
| $5.03M | 1.51% | 566,695 | – | – |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $4.89M | 1.47% | 733,239 -33,604 | -4% | -$224K |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $4.84M | 1.45% | 616,032 | – | – |
|
|
25
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.6M | 1.38% | 551,500 +300,500 | +120% | +$2.51M |
|